ClinicalTrials.gg
CompletedNCT07174531VIVUpdated Sep 16, 2025

Renato® Transcatheter Valve-in-Valve System Multicenter Registry Trial (China)

An interventional study of Transcatheter valve in Valve implantation in Bioprosthesis Failure, sponsored by Beijing Balance Medical Technology Co., Ltd. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Beijing Balance Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 3 months after the study started (first participant enrolled May 2021, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Sex
All
01

Study summary

The Renato® transcatheter valve-in-valve system, developed by Balance Medical, is undergoing a multicenter registry trial across China. The study enrolls patients whose previously implanted surgical or transcatheter bioprosthetic valves have deteriorated and who are at high risk for repeat open-heart surgery. A new bioprosthetic valve is delivered via a transcatheter approach and positioned inside the failing valve, restoring valve function .

02

Conditions studied

  • Bioprosthesis Failure

Keywords

  • Valve-in-Valve
  • Renato
  • Aortic Valve Replacement
  • Tricuspid Valve Replacement
  • Mitral Valve Replacement
03

In context

Lead sponsor

Beijing Balance Medical Technology Co., Ltd is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pre-existing bioprosthetic valve with structural deterioration (≥ moderate stenosis or regurgitation) in the mitral, aortic, or tricuspid position, mandating re-intervention.
  2. Estimated high surgical risk (STS predicted risk of mortality ≥ 8 %) or formal to redo surgical as confirmed by an independent multidisciplinary heart-team review.

Exclusion criteria

Exclusion Criteria:

  1. Small true internal diameter of the failing bioprosthesis deemed unsuitable for valve-in-valve therapy by the independent heart-team.
  2. Failed mitral bioprosthesis with estimated post-procedural left-ventricular outflow tract obstruction (LVOTO) gradient ≥ 30 mmHg or LVOTO risk classified as "high" by the independent heart-team.
  3. Failed tricuspid bioprosthesis with concomitant severe pulmonary hypertension (systolic pulmonary artery pressure > 60 mmHg).
  4. Any additional native or prosthetic valve lesion requiring concomitant surgical intervention, as determined by the independent heart-team.
  5. More than trivial paravalvular leak around the failing bioprosthesis.
  6. Intracardiac thrombus, mass, or vegetation documented by imaging.
  7. Myocardial infarction, coronary-stent implantation, cardiac rhythm-device implantation, stroke, or within 30 days before screening.
  8. Significant coronary artery disease mandating revascularization.
  9. Active infective endocarditis within 6 months of screening.
  10. Active infection requiring systemic antibiotic therapy at the time of screening.
  11. \< 12 months for any non-cardiac condition.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Prosthesis Failure Valve Replacement

    Transcatheter valve-in-valve implantation for patients with degenerated aortic/mitral/tricuspid bioprosthetic valves who are at high-risk to redo surgical valve replacement.

    Procedure: Transcatheter valve in Valve implantation

Interventions

  • ProcedureTranscatheter valve in Valve implantation

    Transcatheter valve-in-valve implantation for patients with degenerated aortic/mitral/tricuspid bioprosthetic valves who are at high-risk to redo surgical valve replacement.

06

What researchers measure

Primary outcomes

  1. All-cause death

    Cardiac and non-cardiac mortality will be captured for all enrolled patients.

    Time frame: 12 months.

Secondary outcomes

  1. Safety Parameters

    Incidence of major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction, stroke, permanent pacemaker implantation, or rehospitalization due to heart failure,

    Time frame: 12 months

07

Study locations

1 site
  • Balance Medical
    Beijing, China
08

References and documents

Publications

  • Chen J, Yang Y, Song W, Feng D, Yan Y, Wang C, Wei L. Transcatheter tricuspid valve-in-valve implantation for degenerated surgical bioprosthesis. Catheter Cardiovasc Interv. 2023 Feb 1;101(2):442-448. doi: 10.1002/ccd.30554. Epub 2023 Jan 8. PubMed 36617381 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in May 2023, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 16, 2025
StartActual
May 25, 2021
Primary completionActual
May 20, 2023
CompletionActual
Sep 28, 2023
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07174531
Lead sponsor
Beijing Balance Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
May 25, 2021
Primary completion
May 20, 2023
Completion
Sep 28, 2023
Last update
Sep 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion